Cytokinetics, Incorporated (CYTK) stock analysis
CYTK · Cytokinetics, Incorporated
Latest recorded price: USD 53.17
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -2.4%, free cash flow margin -607.5%. The model flags 1 risk signal for this company (1 high severity).
Similar companies in Healthcare
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)
- Halozyme Therapeutics, Inc. (HALO)
- Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
- ImmunityBio, Inc. (IBRX)
- IDEAYA Biosciences, Inc. - Common Stock (IDYA)